Harvard Bioscience director granted 16,556 RSUs
DENELSKY STEPHEN J reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
DENELSKY STEPHEN J reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Stephen J. Denelsky received a grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this award, Denelsky holds 37,556 shares and RSUs in total, including 10,000 shares of common stock purchased on March 17, 2026 and 11,000 RSUs scheduled to fully vest on September 5, 2026. The filing notes that these 11,000 RSUs were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 16,556 shares
Grant/Award
1 txn
Insider
DENELSKY STEPHEN J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 16,556 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 37,556 shares (Direct)
Footnotes (3)
- F1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
- F2. Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026.
- F3. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Key Figures
RSU grant size: 16,556 RSUs
Holdings after transaction: 37,556 shares/RSUs
Previously purchased shares: 10,000 shares
+2 more
5 metrics
RSU grant size
16,556 RSUs
Award of restricted stock units to director on June 9, 2026
Holdings after transaction
37,556 shares/RSUs
Total reported holdings following the RSU award
Previously purchased shares
10,000 shares
Common stock purchased on March 17, 2026
Existing RSUs
11,000 RSUs
Restricted stock units fully vesting on September 5, 2026
Reverse stock split ratio
10-for-1
Harvard Bioscience reverse stock split on March 13, 2026
Key Terms
restricted stock units, reverse stock split, vests in full, annual meeting
4 terms
restricted stock units financial
"Represents an award of 16,556 restricted stock units that vests in full"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
reverse stock split financial
"underwent a reverse stock split in a ratio of 10-for-1"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
vests in full financial
"restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting"
annual meeting financial
"immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HBIO director Stephen Denelsky report in this Form 4 filing?
Stephen Denelsky reported receiving 16,556 restricted stock units of Harvard Bioscience common stock. The RSUs are a compensation-related equity award, not an open-market purchase, and increase his total reported holdings to 37,556 shares and RSUs combined.
How do the 16,556 RSUs granted to HBIO director Denelsky vest?
The 16,556 restricted stock units vest in full on the earlier of two dates. They vest either immediately before Harvard Bioscience’s next annual meeting or one year from the grant date, providing a time-based incentive tied to continued board service.
What are Stephen Denelsky’s total reported holdings in HBIO after this award?
After the RSU grant, Stephen Denelsky’s reported holdings total 37,556 shares and RSUs. This includes the new 16,556-unit award, 10,000 shares of common stock purchased on March 17, 2026, and 11,000 RSUs scheduled to vest on September 5, 2026.
How did Harvard Bioscience’s reverse stock split affect Denelsky’s RSUs?
On March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split. As a result, Denelsky’s previously reported 110,000 restricted stock units were adjusted to 11,000 RSUs, aligning the award size with the new post-split share count.
AI-generated analysis. How Rhea-AI works. Not financial advice.
